A new, retrospective study trying to tease out the benefits of MitraClip procedures according to the etiology of mitral regurgitation (MR) hints that, compared with conservative management, ...

Hospitals that perform a larger number of transcatheter mitral valve repairs (TMVRs) with the MitraClip (Abbott) have significantly better procedural success, as well as shorter procedural times and ...

Abbott Laboratories (NYSE:ABT) recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous ...

NEW ORLEANS — To much acclaim, the COAPT trial demonstrated that use of the MitraClip (Abbott) in a very sick population with symptomatic (heart failure (HF) and secondary mitral regurgitation (MR) ...

April 5, 2011 (New Orleans, Louisiana)-Results from the EVEREST IItrial out to two years show that percutaneous repair of the mitral valve with the MitraClip (Abbott) device was significantly less ...

Abbott has announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip® System for the ...

BOSTON -- Contemporary practice had the fourth-generation MitraClip producing low short-term mortality and other good results even in mitral regurgitation (MR) patients previously deemed unsuitable ...

On February 15, FDA announced that Abbott Vascular has received nine reports of its MitraClip delivery system failing to detach from the Clip, which resulted in the death of one patient and open-heart ...

SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...

Abbott Lifesciences (NYSE:ABT) recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous ...